Patents by Inventor Changyi Chen

Changyi Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190194663
    Abstract: A novel network of tumorigenic prognostic factors is identified that plays a critical role in advanced pancreatic cancer (PC) pathogenesis. This interactome is interconnected through a central tumor suppressive microRNA, miR-198, which is able to both directly and indirectly modulate expression of the various members of this network to alter the molecular makeup of pancreatic tumors, with important clinical implications. When this tumor signature network is intact, miR-198 expression is reduced and patient survival is dismal; patients with higher miR-198 present an altered tumor signature network, better prognosis and increased survival. Further, according to the present disclosure, MiR-198 replacement reverses tumorigenicity in vitro and in vivo.
    Type: Application
    Filed: March 12, 2019
    Publication date: June 27, 2019
    Inventors: Qizhi Yao, Christian Marin-Muller, Changyi Chen
  • Publication number: 20190194396
    Abstract: Embodiments of the invention concern copolymers and nanoparticles for use as delivery agents for one or more agents for therapy for a medical condition of humans and animals. Some of embodiments of the invention provide new reagents for biomedical research in cell culture, animal models and plants, for example. The copolymers comprise PLGA and PEI and, in some embodiments, also comprise 1-(3-aminopropyl)-4-methylpiperazine (APMP), Fc binding peptide and/or antibody. In certain embodiments, APMP-PLGA-PEI, Fc binding peptide/antibody-PLGA-PEI or Fc binding peptide/antibody-APMP-PLGA-PEI nanoparticles comprising one or more therapeutic agents are delivered to an individual in need thereof or used for biomedical research in cell cultures, animal models and plants.
    Type: Application
    Filed: March 8, 2019
    Publication date: June 27, 2019
    Inventors: Jian-Ming Lu, Qizhi Yao, Changyi Chen
  • Patent number: 10246560
    Abstract: Embodiments of the invention concern copolymers and nanoparticles for use as delivery agents for one or more agents for therapy for a medical condition of humans and animals. Some of embodiments of the invention provide new reagents for biomedical research in cell culture, animal models and plants, for example. The copolymers comprise PLGA and PEI and, in some embodiments, also comprise 1-(3-aminopropyl)-4-methylpiperazine (APMP), Fc binding peptide and/or antibody. In certain embodiments, APMP-PLGA-PEI, Fc binding peptide/antibody-PLGA-PEI or Fc binding peptide/antibody-AP-MP-PLGA-PEI nanoparticles comprising one or more therapeutic agents are delivered to an individual in need thereof or used for biomedical research in cell cultures, animal models and plants.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: April 2, 2019
    Assignee: Baylor College of Medicine
    Inventors: Jian-Ming Lu, Qizhi Yao, Changyi Chen
  • Publication number: 20180346914
    Abstract: A novel network of tumorigenic prognostic factors is identified that plays a critical role in advanced pancreatic cancer (PC) pathogenesis. This interactome is interconnected through a central tumor suppressive microRNA, miR-198, which is able to both directly and indirectly modulate expression of the various members of this network to alter the molecular makeup of pancreatic tumors, with important clinical implications. When this tumor signature network is intact, miR-198 expression is reduced and patient survival is dismal; patients with higher miR-198 present an altered tumor signature network, better prognosis and increased survival. Further, according to the present disclosure, MiR-198 replacement reverses tumorigenicity in vitro and in vivo.
    Type: Application
    Filed: April 17, 2018
    Publication date: December 6, 2018
    Inventors: Qizhi Yao, Christian Marin-Muller, Changyi Chen
  • Patent number: 9622988
    Abstract: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: April 18, 2017
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: Changyi Chen, Jian-Ming Lu, Qizhi Yao
  • Patent number: 9610257
    Abstract: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: April 4, 2017
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: Changyi Chen, Jian-Ming Lu, Qizhi Yao
  • Publication number: 20170081666
    Abstract: A novel network of tumorigenic prognostic factors is identified that plays a critical role in advanced pancreatic cancer (PC) pathogenesis. This interactome is interconnected through a central tumor suppressive microRNA, miR-198, which is able to both directly and indirectly modulate expression of the various members of this network to alter the molecular makeup of pancreatic tumors, with important clinical implications. When this tumor signature network is intact, miR-198 expression is reduced and patient survival is dismal; patients with higher miR-198 present an altered tumor signature network, better prognosis and increased survival. Further, according to the present disclosure, MiR-198 replacement reverses tumorigenicity in vitro and in vivo.
    Type: Application
    Filed: December 8, 2016
    Publication date: March 23, 2017
    Inventors: Qizhi Yao, Christian Marin-Muller, Changyi Chen
  • Patent number: 9585848
    Abstract: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: March 7, 2017
    Assignee: Baylor College of Medicine
    Inventors: Changyi Chen, Jian-Ming Lu, Qizhi Yao
  • Patent number: 9585847
    Abstract: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: March 7, 2017
    Assignee: Baylor College of Medicine
    Inventors: Changyi Chen, Jian-Ming Lu, Qizhi Yao
  • Patent number: 9580379
    Abstract: Small molecule xanthine oxidase inhibitors are provided, as well as compositions, methods for their use for treating disorders, mediated at least in part, by xanthine oxidase.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: February 28, 2017
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: Changyi Chen, Qizhi Yao, Jian-Ming Lu
  • Patent number: 9546365
    Abstract: A novel network of tumorigenic prognostic factors is identified that plays a critical role in advanced pancreatic cancer (PC) pathogenesis. This interactome is interconnected through a central tumor suppressive microRNA, miR-198, which is able to both directly and indirectly modulate expression of the various members of this network to alter the molecular makeup of pancreatic tumors, with important clinical implications. When this tumor signature network is intact, miR-198 expression is reduced and patient survival is dismal; patients with higher miR-198 present an altered tumor signature network, better prognosis and increased survival. Further, according to the present disclosure, MiR-198 replacement reverses tumorigenicity in vitro and in vivo.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: January 17, 2017
    Assignee: Baylor College of Medicine
    Inventors: Qizhi Yao, Christian Marin-Muller, Changyi Chen
  • Publication number: 20160184443
    Abstract: Embodiments of the invention concern copolymers and nanoparticles for use as delivery agents for one or more agents for therapy for a medical condition of humans and animals. Some of embodiments of the invention provide new reagents for biomedical research in cell culture, animal models and plants, for example. The copolymers comprise PLGA and PEI and, in some embodiments, also comprise 1-(3-aminopropyl)-4-methylpiperazine (APMP), Fc binding peptide and/or antibody. In certain embodiments, APMP-PLGA-PEI, Fc binding peptide/antibody-PLGA-PEI or Fc binding peptide/antibody-AP-MP-PLGA-PEI nanoparticles comprising one or more therapeutic agents are delivered to an individual in need thereof or used for biomedical research in cell cultures, animal models and plants.
    Type: Application
    Filed: August 13, 2014
    Publication date: June 30, 2016
    Inventors: Jian-Ming Lu, Qizhi Yao, Changyi Chen
  • Publication number: 20160089342
    Abstract: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.
    Type: Application
    Filed: April 7, 2015
    Publication date: March 31, 2016
    Inventors: Changyi Chen, Jian-Ming Lu, Qizhi Yao
  • Publication number: 20150353471
    Abstract: Small molecule xanthine oxidase inhibitors are provided, as well as compositions, methods for their use for treating disorders, mediated at least in part, by xanthine oxidase.
    Type: Application
    Filed: October 7, 2014
    Publication date: December 10, 2015
    Inventors: Changyi Chen, Qizhi YAO, Jian-Ming LU
  • Publication number: 20150211009
    Abstract: A novel network of tumorigenic prognostic factors is identified that plays a critical role in advanced pancreatic cancer (PC) pathogenesis. This interactome is interconnected through a central tumor suppressive microRNA, miR-198, which is able to both directly and indirectly modulate expression of the various members of this network to alter the molecular makeup of pancreatic tumors, with important clinical implications. When this tumor signature network is intact, miR-198 expression is reduced and patient survival is dismal; patients with higher miR-198 present an altered tumor signature network, better prognosis and increased survival. Further, according to the present disclosure, MiR-198 replacement reverses tumorigenicity in vitro and in vivo.
    Type: Application
    Filed: February 5, 2015
    Publication date: July 30, 2015
    Inventors: Qizhi Yao, Christian Marin-Muller, Changyi Chen
  • Patent number: 9061983
    Abstract: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: June 23, 2015
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: Changyi Chen, Jian-Ming Lu, Qizhi Yao
  • Patent number: 8987337
    Abstract: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: March 24, 2015
    Assignee: Baylor College of Medicine
    Inventors: Changyi Chen, Jian-Ming Lu, Qizhi Yao
  • Patent number: 8987224
    Abstract: A novel network of tumorigenic prognostic factors is identified that plays a critical role in advanced pancreatic cancer (PC) pathogenesis. This interactome is interconnected through a central tumor suppressive microRNA, miR-198, which is able to both directly and indirectly modulate expression of the various members of this network to alter the molecular makeup of pancreatic tumors. When this tumor signature network is intact, miR-198 expression is reduced and patient survival is dismal; patients with higher miR-198 present an altered tumor signature network, better prognosis and increased survival. Further, MiR-198 replacement reverses tumorigenicity in vitro and in vivo. embodiment of the disclosure is a method of treating cancer in an individual, comprising the step of increasing the level of active microRNA-198 molecules in the pancreatic cancer tumor cells of the individual by an amount sufficient to cause an improvement in the pancreatic cancer in the individual.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: March 24, 2015
    Assignee: Baylor College of Medicine
    Inventors: Qizhi Yao, Christian Marin-Muller, Changyi Chen
  • Publication number: 20150005389
    Abstract: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.
    Type: Application
    Filed: September 10, 2014
    Publication date: January 1, 2015
    Inventors: Changyi Chen, Jian-Ming Lu, Qizhi Yao
  • Publication number: 20150004699
    Abstract: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.
    Type: Application
    Filed: September 10, 2014
    Publication date: January 1, 2015
    Inventors: Changyi Chen, Jian-Ming Lu, Qizhi Yao